Both stocks run through our valuation models. Here is how Cipla (CIPLA) and Eli Lilly and (LLY) compare, as of Aug 20, 2026.
As of Aug 20, 2026, Fair Value Calculator sees Cipla as the more attractively valued of the two: Cipla trades at ₹1,422 versus a fair value of ₹1,801 (+27%), while Eli Lilly and trades at $1,280 versus $389 (-70%).
Cipla
CIPLA.NSE · INR · Health Care
+27%
upside to fair value
undervalued
Price₹1,422
Fair Value₹1,801
Quality55/100
Eli Lilly and
LLY · USD · Health Care
-70%
upside to fair value
overvalued
Price$1,280
Fair Value$389
Quality69/100
Get comparisons like this free by email every month: the most undervalued quality stocks.
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
CiplaEli Lilly and
Valuation
30.5×P/E (TTM)42.2×
4.18×P/S (TTM)14.67×
3.38×P/B39.94×
19.9×EV/EBITDA30.2×
—PEG1.54×
0.9%Dividend yield0.5%
₹13.00Dividend per share$6.23
Profitability
14%Net margin35%
11%Operating margin49%
12%Return on equity107%
8%Return on assets21%
Growth
-2%Revenue growth (YoY)56%
7.7%Avg. growth/yr (3Y)31.7%
8.1%Avg. growth/yr (5Y)21.6%
Balance & size
0.00×Debt / equity1.54×
$12BMarket cap$1.1T
mixedGrowth qualitymixed
Eli Lilly and leads: 6 to 7 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Ciplaof which business quality 55 · market factors 57Eli Lilly andof which business quality 65 · market factors 86
ProfitabilityMargins and returns on capital today
53
85
Quality GrowthAre margins and returns improving?
13
86
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
49
15
Low VolatilityCalm price path (market factor)
94
77
MomentumPrice trend over the last 3–12 months (market factor)
42
84
52W MomentumDistance to the 52-week high (market factor)
39
100
Net IssuanceBuybacks instead of dilution
82
93
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Cipla
DCF Models₹1,541
Earnings-Based₹1,681
Dividend Discount₹306
Multiples₹910
Asset-Based₹286
Growth DCF₹1,166
Economic Profit₹545
Growth Earnings₹2,231
18 of 26 models see the stock below the current price.
Eli Lilly and
DCF Models$334
Earnings-Based$239
Dividend Discount$115
Multiples$358
Asset-Based$19.94
Growth DCF$187
Economic Profit$347
Growth Earnings$375
26 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Cipla
Bear ₹1,166Fair Value ₹1,801Bull ₹2,247
₹1,422 = current price (white tick)
Eli Lilly and
Bear $216Fair Value $389Bull $582
$1,280 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Cipla · Health Care
Quality score55 · above median
Fair value upside+27% · Top 25%
Eli Lilly and · Health Care
Quality score69 · Top 25%
Fair value upside-70% · bottom 25%
Bottom line
As of Aug 20, 2026, Fair Value Calculator sees Cipla as the more attractively valued of the two: Cipla trades at ₹1,422 versus a fair value of ₹1,801 (+27%), while Eli Lilly and trades at $1,280 versus $389 (-70%).
Eli Lilly and has the higher quality score (69/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
